Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB Cause Systemic lupus erythematosus? 8,819 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 8,819 reports of Systemic lupus erythematosus have been filed in association with RITUXIMAB (Rituxan). This represents 4.9% of all adverse event reports for RITUXIMAB.

8,819
Reports of Systemic lupus erythematosus with RITUXIMAB
4.9%
of all RITUXIMAB reports
2,003
Deaths
2,874
Hospitalizations

How Dangerous Is Systemic lupus erythematosus From RITUXIMAB?

Of the 8,819 reports, 2,003 (22.7%) resulted in death, 2,874 (32.6%) required hospitalization, and 2,279 (25.8%) were considered life-threatening.

Is Systemic lupus erythematosus Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB. However, 8,819 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB Cause?

Off label use (39,751) Drug ineffective (32,186) Rheumatoid arthritis (19,850) Pain (16,675) Fatigue (15,602) Arthralgia (12,529) Rash (12,102) Drug intolerance (11,876) Infusion related reaction (11,871) Joint swelling (11,170)

What Other Drugs Cause Systemic lupus erythematosus?

ADALIMUMAB (11,880) METHOTREXATE (9,350) INFLIXIMAB (9,071) ABATACEPT (8,944) HYDROXYCHLOROQUINE (8,867) PREDNISONE (8,799) LEFLUNOMIDE (8,669) TOCILIZUMAB (8,656) FOLIC ACID (8,360) CERTOLIZUMAB PEGOL (8,212)

Which RITUXIMAB Alternatives Have Lower Systemic lupus erythematosus Risk?

RITUXIMAB vs RITUXIMAB-ABBS RITUXIMAB vs RITUXIMAB-ARRX RITUXIMAB vs RITUXIMAB-PVVR RITUXIMAB vs RIVAROXABAN RITUXIMAB vs RIVASTIGMINE

Related Pages

RITUXIMAB Full Profile All Systemic lupus erythematosus Reports All Drugs Causing Systemic lupus erythematosus RITUXIMAB Demographics